Review Papers Claim by Claim

 Quick Explanation Copied

 Long Explanation

What the paper reports

Gydesen et al. present 17 years of data on a single large Jutland pedigree: 22 affected individuals across three generations, autosomal dominant inheritance with high penetrance, mean onset 57 years (range 46–65), mean disease duration 8 years, and death typically from pneumonia or intercurrent illness Gydesen et al. FTD-3 clinical genetics. The phenotype begins with personality change, disinhibition, and hyperorality; dyscalculia appears early; late stages bring pyramidal, extrapyramidal, and myoclonic features. Five autopsies uniformly showed neuronal loss and gliosis without plaques, tangles, or characteristic inclusions—criterion-defining for the "dementia lacking distinctive histopathology" category.

The key quantitative evidence: global hypoperfusion

The most distinctive finding is O-15-water PET in two patients. Even Case III-22 (age 64, MMSE 24—mild disease) showed pronounced rCBF deficits across all secondary cortices, while primary visual cortex, thalamus, basal ganglia, and cerebellum were spared. Because cerebellar flow was normal, the authors argue the cortical deficit reflects metabolic decline, not a vascular process. This global pattern contrasts with the frontal-only rCBF reduction reported for FTDP-17 FTD-3 PET rCBF Table 1 data.

Note: hemisphere values were averaged only for display; the paper reports right and left separately and did not publish an unaffected control mean, so "deficit" is defined relative to normative probability maps, not shown numerically.

How the field resolved the open question

The paper's central limitation—no identified causative mutation—was resolved post hoc. A 2003 follow-up found sparse tau filament deposits (60/64/68 kDa bands, AD-like) in the same family's frontal cortex without beta-amyloid, in cases II-12, III-13, and III-17 Tau protein analysis in FTD-3 frontal cortex—partially revising the 2002 claim of tau-negativity. In 2008, a truncating splice-site mutation (c.532-1G>C) in CHMP2B, an endosomal sorting gene on chromosome 3, was identified in a previously unknown branch of the family CHMP2B truncating mutation in FTD-3, confirming FTD-3 as a genuine genetic entity and implicating the endolysosomal/ESCRT pathway in FTD pathogenesis—a mechanism the 2002 paper could not have anticipated.

Critical assessment

• Strengths: exceptional longitudinal pedigree ascertainment (17 years), multi-modal characterization, and honest self-correction—the authors explicitly retract their earlier anticipation finding after two new paternal-transmission cases showed later onset than their fathers.
• Blind spots: n=1 family severely limits generalizability; only one patient was neuropsychologically tested early; all patients with the late motor syndrome had neuroleptic exposure, so drug contribution to the extrapyramidal picture cannot be excluded (the authors note this but do not resolve it); white matter myelin loss may be secondary or coincidental small-vessel disease.
• Self-correction needed later: the "lacks distinctive histopathology" framing was revised by the 2003 tau-filament data, illustrating how classification categories of the era were unstable.
• The chromosome 9p ALS-FTD locus, cited in the paper as a comparator, was independently pursued in other families with multipoint LOD up to 7.22 Chromosome 9p ALS-FTD linkage families, validating the paper's three-way genetic taxonomy (FTDP-17 / FTD-3 / MND-dementia) as a prescient framework.

What would change this assessment: evidence that the widespread cortical hypoperfusion in early disease reflects a comorbid process rather than CHMP2B-related pathology, or that non-Danish CHMP2B families show a materially different phenotype, would weaken the paper's central genotype-phenotype claim.

 BGPT Paper Review

Study Novelty

For 2002, establishing a novel chromosome 3-linked FTD locus with full clinical-pathologic characterization was groundbreaking; CHMP2B confirmation came only in 2008.

Scientific Quality

Rigorous multimodal characterization with honest retraction of the anticipation claim; weaknesses are single-family design, only two PET scans, and minimal early-stage neuropsychology.

Study Generality

Findings are pedigree-specific; the genetic taxonomy framework generalizes, but phenotype details may not transfer to other CHMP2B or FTD cohorts.

Study Usefulness

Anchored FTD genetic classification, enabled later CHMP2B mutation screening in Danish FTD, and provided a reference phenotype for familial FTD differential diagnosis.

Study Reproducibility

Methods (PET protocol, histology panel) are described, but the family is unique and largely historical; independent replication of the full phenotype is essentially impossible.

Explanatory Depth

Deep descriptive phenotyping, but no mechanistic explanation was possible pre-gene-identification; causal pathobiology awaited CHMP2B discovery.